Virginia Hancock
Family · New Bern, NCNPI 1457750267
Payments from drug & device makers
Across 207 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$761
- Abbott$394
- Amgen$291
- Teva Pharmaceuticals USA, Inc.$170
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$136
- plus $803 from 17 others
What the payments were for
- Food & beverage$3,90598%
- Education$812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 90 | $1,431 |
| AstraZeneca | 16 | $761 |
| Abbott | 22 | $394 |
| Amgen | 19 | $291 |
| Teva Pharmaceuticals USA, Inc. | 6 | $170 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $136 |
| Pfizer | 8 | $124 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| Neurocrine Biosciences, Inc. | 2 | $77 |
| Novo Nordisk | 4 | $62 |
| Exact Sciences | 4 | $62 |
| Gilead | 3 | $62 |
| GSK | 4 | $55 |
| Xeris Pharmaceuticals, Inc. | 2 | $47 |
| Boehringer Ingelheim | 3 | $39 |
| Ardelyx, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Medtronic | 1 | $26 |
| Astellas Pharma US Inc | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$132
- BREZTRI$124
- VRAYLAR$120
- FARXIGA$102
How this compares
$3,987 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 113 | $131,849 |
| JardianceEmpagliflozin | 82 | $91,836 |
| MounjaroTirzepatide | 70 | $84,253 |
| FarxigaDapagliflozin Propanediol | 102 | $81,480 |
| VraylarCariprazine Hcl | 54 | $80,837 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $36,514 |
| LinzessLinaclotide | 37 | $26,612 |
| TrulicityDulaglutide | 25 | $24,984 |
| XareltoRivaroxaban | 29 | $23,290 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $20,270 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $13,034 |
| Repatha SureclickEvolocumab | 19 | $12,662 |
| EliquisApixaban | 17 | $12,240 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $9,878 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $9,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $62 | $131,849113 claims |
| Lilly USA, LLCMounjaro, Trulicity | $18 | $109,23795 claims |
| AbbVieVraylar, Linzess | $1,431 | $107,44991 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $761 | $105,747148 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $39 | $97,54093 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $55 | $49,54872 claims |
| PfizerEliquis | $124 | $12,24017 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $7,11113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.
Other family in New Bern
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.